AUS
NZ
UK
CA
USA
IND
.jpg)
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company focused on developing innovative small molecule drugs for virology and immunology, has announced encouraging topline results from a Phase 2a human challenge study of EDP-323, a novel treatment for respiratory syncytial virus (RSV). This study marks a significant step forward in the quest for effective therapies against RSV, a virus that poses a serious health risk, particularly to infants and the elderly.
The Phase 2a study included 142 healthy adult participants who were inoculated with RSV. The trial was designed as a randomized, double-blind, placebo-controlled study, wherein participants received either a high dose of 600 mg of EDP-323 once daily for five days, a lower dose of 600 mg on the first day followed by 200 mg for the next four days, or a placebo. Notably, the results indicated that EDP-323 was generally safe and well-tolerated among participants.
The efficacy of EDP-323 was compelling, showcasing an impressive 85-87% reduction in viral load area under the curve (AUC) as measured by quantitative reverse transcription PCR (qRT-PCR) compared to placebo (p<0.0001). Additionally, there was a remarkable 97-98% reduction in infectious viral load AUC determined through viral culture (p<0.0001), and a 66-78% reduction in total clinical symptom scores AUC (p<0.0001). These results are among the strongest ever reported in RSV challenge studies, positioning EDP-323 as a promising candidate for future RSV treatments.
Dr. Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals, expressed his enthusiasm regarding the study's findings. “We are excited about these impressive data that demonstrate a rapid and sustained reduction in viral load. The significant antiviral activity and symptom alleviation observed in this study highlight EDP-323’s potential as a safe, highly effective, direct-acting antiviral for the treatment of RSV,” he stated.
Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals, emphasized the importance of these results in the context of existing treatment gaps. “These EDP-323 results represent a meaningful advancement toward achieving our longstanding goal of developing new medicines to treat respiratory infections such as RSV, as there remains a substantial need for safe and effective oral treatments,” he noted. He further elaborated on Enanta's strategic positioning in the RSV space, highlighting the company’s leading portfolio of potent RSV replication inhibitors, which includes both EDP-323 and zelicapavir, another candidate in Phase 2 development.
The study's primary efficacy endpoint demonstrated a highly statistically significant reduction in viral load AUC across both dosing regimens of EDP-323 compared to placebo. In the intent-to-treat-infected population, the high dose achieved an 85% reduction, while the low dose achieved a 87% reduction, showcasing the drug's potential efficacy.
As Enanta Pharmaceuticals moves forward, the results of this study will be critical in shaping the future development of EDP-323 as a potential once-daily oral treatment for RSV. With its Fast Track designation from the U.S. Food and Drug Administration (FDA), EDP-323 is well-positioned to make a substantial impact on public health, particularly for vulnerable populations affected by respiratory infections. As the company continues to innovate and push the boundaries of treatment options, the fight against RSV may soon see a significant advancement, ultimately improving outcomes for countless patients.
